Immediately after publication of the original article, the authors found that the incorrect versions of Figure 1B and Table 2 were included due to human error. The correct version of Figure 1 and Table 2 are included in this Corrigendum.
Figure 1
Table 2
| Time (min) | Plasma (ng/mL, mean ±SD) | Aqueous humor (ng/mL, mean ±SD) | Cornea (μg/g, mean ±SD) | Conjunctiva (μg/g, mean ±SD) | Tear fluid (μg/g, mean ±SD) |
|---|---|---|---|---|---|
| 2 | 103.61 ± 28.37 | 119.43 ± 37.92 | 216.83 ± 78.05 | 267.88 ± 75.51 | 333.42 ± 69.72 |
| 10 | 263.87 ± 80.96 | 112.94 ± 15.10 | 291.02 ± 109.25 | 261.29 ± 66.47 | 208.93 ± 30.82 |
| 30 | 109.16 ± 33.00 | 62.80.24 ± 7.29 | 762.86 ± 385.68 | 178.23 ± 35.22 | 154.98 ± 73.25 |
Concentration of TSA in tissues and plasma after topical application in eye*.
Peaks were referenced with commercial standard from Assay Matrix Pty Ltd.
Prasad Neerati was not included as an author in the published article. HPLC data in Table 2 was repeated and now Prasad Neerati is included in the list of authors in the article. The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
survivin, haze, scarring, wound healing, cytokines, trichostatin-A
Citation
Roy K, Neerati P, Cheung CHA, Kanwar RK, Sandhir R and Kanwar JR (2018) Corrigendum: Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze. Front. Pharmacol. 9:1434. doi: 10.3389/fphar.2018.01434
Received
29 October 2018
Accepted
19 November 2018
Published
18 December 2018
Volume
9 - 2018
Edited and reviewed by
Salvatore Salomone, Università degli Studi di Catania, Italy
Updates
Copyright
© 2018 Roy, Neerati, Cheung, Kanwar, Sandhir and Kanwar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jagat R. Kanwar jagat.kanwar@deakin.edu.au
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.